Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained
Related Experiment Video
Updated: Sep 28, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
J S Wolinsky1, G Comi, M Filippi
1The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA. Jerry.S.Wolinsky@uth.tmc.edu
Abstract:
All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Multiple Sclerosis l: Introduction
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Therapeutic Drug Monitoring: Affecting Factors

